Pharmacotherapy for leptomeningeal disease in breast cancer
Cancer Treatment Reviews · 2024-01 · 122 · 102653
DOI: 10.1016/j.ctrv.2023.102653 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2024-01. Verfasst von Rupert Bartsch und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine I, Division of Oncology, Medical University Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Breast Neoplasms, Meningeal Carcinomatosis, Meningeal Neoplasms. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Seagen Inc.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine I, Division of Oncology, Medical University Vienna, Vienna, Austria.
- Division of Medical Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
- Centre Léon Bérard, Lyon, France.
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Departments of Neurosurgery and Neurology, University Hospital of Zurich, Zurich, Switzerland. Electronic address: emilie.lerhun@usz.ch.
Förderung
- Seagen Inc
Zitieren
APA
Bartsch, R., Jerzak, K. J., Larrouquere, L., Müller, V., & Le Rhun, E. (2024). Pharmacotherapy for leptomeningeal disease in breast cancer. Cancer Treatment Reviews, 122, 102653. https://doi.org/10.1016/j.ctrv.2023.102653
Vancouver
Bartsch R, Jerzak KJ, Larrouquere L, Müller V, Le Rhun E. Pharmacotherapy for leptomeningeal disease in breast cancer. Cancer Treatment Reviews. 2024;122:102653. doi:10.1016/j.ctrv.2023.102653
BibTeX
@article{Bartsch2024,
author = {Bartsch, Rupert and Jerzak, Katarzyna J and Larrouquere, Louis and Müller, Volkmar and Le Rhun, Emilie},
title = {Pharmacotherapy for leptomeningeal disease in breast cancer},
journal = {Cancer Treatment Reviews},
year = {2024},
volume = {122},
pages = {102653},
doi = {10.1016/j.ctrv.2023.102653}
}
EUVIMED